, Volume 20, Issue 3, pp 319–324 | Cite as

SOCS2 polymorphisms are not associated with clinical and biochemical phenotypes in acromegalic patients

  • Ericka B. TrarbachEmail author
  • Alexander A. Jorge
  • Felipe H. Duarte
  • Marcello D. Bronstein
  • Raquel S. Jallad



Suppressor of cytokine signaling 2 (SOCS2) is a STAT5b-regulated gene and one of its functions is to influence growth and development through negative regulatory effects on GH/IGF-1 pathway. So, we evaluate the potential influence of SOCS2 single nucleotide polymorphisms (SNPs) on clinical and laboratorial characteristics of a large cohort of Brazilian patients with acromegaly.


Four SOCS2 SNPs (rs3782415, rs3816997, rs3825199 and rs11107116) were selected and genotyped by real-time PCR using specific Taqman probe assays. A total of 186 patients (116 women, age range 26–88 years) were evaluated.


No association of SOCS2 genotypes was observed with none of the following clinical and laboratorial characteristics: age, sex, body mass index, comorbidities, basal GH, oral glucose tolerance test GH nadir, IGF-I, ULNR-IGF-I.


Despite of the key role of SOCS2 in the regulation of GH receptor signaling, we did not find any significant association between SOCS2 polymorphisms and acromegaly.


SOCS2 polymorphism Acromegaly GH-signaling Co-morbidities 



We thanks to Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) for the financial support.


This study was funded in part by Fundação de Amparo à Pesquisa do Estado de São Paulo – FAPESP (Grant Number 2010/11718-1).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Lugo G, Pena L, Cordido F (2012) Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol 2012:540398CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Adelman DT, Liebert KJ, Nachtigall LB, Lamerson M, Bakker B (2013) Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment. Int J Gen Med 6:31–38CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL (2002) Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87:3537–3542CrossRefPubMedGoogle Scholar
  4. 4.
    Freda PU (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin Endocrinol (Oxf) 71:166–170CrossRefGoogle Scholar
  5. 5.
    Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD (2004) Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 89:495–500CrossRefPubMedGoogle Scholar
  6. 6.
    Mercado M et al (2004) Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res 62:293–299PubMedGoogle Scholar
  7. 7.
    Alexopoulou O et al (2008) Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93:1324–1330CrossRefPubMedGoogle Scholar
  8. 8.
    Machado EO et al (2008) Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 18:389–393CrossRefPubMedGoogle Scholar
  9. 9.
    Elias PC et al (2010) Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity. Horm Metab Res 42:50–55CrossRefPubMedGoogle Scholar
  10. 10.
    Brzana JA et al (2012) Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary 15:562–570CrossRefPubMedGoogle Scholar
  11. 11.
    Hartman ML et al (1990) Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab 70:1375–1384CrossRefPubMedGoogle Scholar
  12. 12.
    Veldhuis JD (1996) Gender differences in secretory activity of the human somatotropic (growth hormone) axis. Eur J Endocrinol 134:287–295CrossRefPubMedGoogle Scholar
  13. 13.
    Peacey SR, Toogood AA, Veldhuis JD, Thorner MO, Shalet SM (2001) The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab 86:259–266CrossRefPubMedGoogle Scholar
  14. 14.
    Matta M et al (2011) Clinical and metabolic characteristics of acromegalic patients with high IGF1/normal GH levels during somatostatin analog treatment. Eur J Endocrinol 164:885–889CrossRefPubMedGoogle Scholar
  15. 15.
    Bianchi A et al (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94:2015–2022CrossRefPubMedGoogle Scholar
  16. 16.
    Cinar N et al (2015) The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly. Pituitary 18:116–125CrossRefPubMedGoogle Scholar
  17. 17.
    Metcalf D et al (2000) Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405:1069–1073CrossRefPubMedGoogle Scholar
  18. 18.
    Paternoster L et al (2011) Adult height variants affect birth length and growth rate in children. Hum Mol Genet 20:4069–4075CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Gudbjartsson DF et al (2008) Many sequence variants affecting diversity of adult human height. Nat Genet 40:609–615CrossRefPubMedGoogle Scholar
  20. 20.
    Braz AF et al (2014) Genetic Predictors of long-term response to growth hormone (GH) therapy in children with GH deficiency and turner syndrome: the influence of a SOCS2 polymorphism. J Clin Endocrinol Metab 99:E1808–E1813CrossRefPubMedGoogle Scholar
  21. 21.
    Rico-Bautista E, Flores-Morales A, Fernández-Pérez L (2006) Suppressor of cytokine signaling (SOCS)2, a protein with multiple functions. Cytokine Growth Factor Rev 17:431–439CrossRefPubMedGoogle Scholar
  22. 22.
    Trengove MC, Ward AC (2013) SOCS proteins in development and disease. Am J Clin Exp Immunol 2:1–29PubMedPubMedCentralGoogle Scholar
  23. 23.
    Jallad RS, Trarbach EB, Duarte FH, Jorge AA, Bronstein MD (2015) Influence of growth hormone receptor (GHR) exon 3 and -202A/C IGFBP-3 genetic polymorphisms on clinical and biochemical features and therapeutic outcome of patients with acromegaly. Pituitary 18:666–673CrossRefPubMedGoogle Scholar
  24. 24.
    Bogazzi F et al (2009) Changes in the expression of suppressor of cytokine signalling (SOCS)2 in the colonic mucosa of acromegalic patients are associated with hyperplastic polyps. Clin Endocrinol (Oxf) 70:898–906CrossRefGoogle Scholar
  25. 25.
    Buslei R et al (2006) Abundant hypermethylation of SOCS-1 in clinically silent pituitary adenomas. Acta Neuropathol 111:264–271CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Ericka B. Trarbach
    • 1
    Email author
  • Alexander A. Jorge
    • 1
  • Felipe H. Duarte
    • 2
  • Marcello D. Bronstein
    • 2
  • Raquel S. Jallad
    • 2
  1. 1.Laboratory of Cellular and Molecular Endocrinology - LIM25Clinical Hospital of the University of São Paulo Medical SchoolSão PauloBrazil
  2. 2.Neuroendocrine Unit, Division of Endocrinology and MetabolismClinical Hospital of the University of São Paulo Medical SchoolSão PauloBrazil

Personalised recommendations